In the present study, NGS analysis detected mutations (other than EGFR mutations for NSCLC and than KRAS and NRAS for CRC) with potential clinical impact for 4 patients with NSCLC (one PIK3CA mutation and 3 STK11 mutations) and for 14 patients with CRC (10 PIK3CA mutations, 5 BRAF mutations—one patient harbouring PIK3CA and BRAF mutations). Here, NRAS is linked to non-small cell lung carcinoma.